Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026332 · ClinicalTrials.gov registry record
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
A clinical trial, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- 202
- Enrollment target
NCT06026332: Clinical Trial study, sponsored by Ferring Pharmaceuticals.
NCT06026332 is a clinical trial that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 202 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06026332 was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- 202 participants
- Enrollment target
Study Summary
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Interventions
- DRUG ADSTILADRIN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2026-01-15 |
Why NCT06026332 stopped before completion
NCT06026332 is an observational study that tracks outcomes without assigning an intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ADSTILADRIN is the first listed.
NCT06026332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06026332 about?
NCT06026332 is a clinical study titled "ADSTILADRIN Early Utilization and Outcomes in the Real World Setting". Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
What is the current status of trial NCT06026332?
This trial is currently terminated. The enrollment target is 202 participants. The study started on 2023-09-15. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT06026332?
The interventions under investigation include: ADSTILADRIN (DRUG).
Who is sponsoring clinical trial NCT06026332?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI